# EDGAR Filing Document

**Accession Number:** 0001476963
**File Stem:** 0001079973-25-001794
**Filing Date:** 2025-11
**Character Count:** 5980
**Document Hash:** f45061efe55e3e24233da9e598407474
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001079973-25-001794.hdr.sgml**: 20251118

**ACCESSION NUMBER**: 0001079973-25-001794

**CONFORMED SUBMISSION TYPE**: NT 10-Q

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251118

**DATE AS OF CHANGE**: 20251118

**EFFECTIVENESS DATE**: 20251118

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Scorpius Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001476963
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 262844103
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NT 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35994
- **FILM NUMBER:** 251493706

**BUSINESS ADDRESS:**
- **STREET 1:** 1305 E. HOUSTON STREET
- **STREET 2:** BUILDING 2
- **CITY:** SAN ANTONIO
- **STATE:** TX
- **ZIP:** 78205
- **BUSINESS PHONE:** 919-240-7133

**MAIL ADDRESS:**
- **STREET 1:** 1305 E. HOUSTON STREET
- **STREET 2:** BUILDING 2
- **CITY:** SAN ANTONIO
- **STATE:** TX
- **ZIP:** 78205

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NightHawk Biosciences, Inc.
- **DATE OF NAME CHANGE:** 20220502

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HEAT BIOLOGICS, INC.
- **DATE OF NAME CHANGE:** 20091117

**U.S. SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 12B-25**

**NOTIFICATION OF LATE FILING**

---

| |
|:---|
| SEC FILE NUMBER**<br> 001-35994** |
| CUSIP NUMBER**<br> 42237K 508** |

---

(*Check One*): ☐ Form 10-K ◻ Form 20-F ◻Form 11-K

☒ Form 10-Q ◻ Form 10-D ◻ Form N-CEN ◻ Form N-CSR

For Period Ended: September 30, 2025

◻ Transition Report on Form 10-K

◻ Transition Report on Form 20-F

◻Transition Report on Form 11-K

◻ Transition Report on Form 10-Q

For the Transition Period Ended: N/A

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *Read Instruction (on back page) Before Preparing Form. Please Print or Type.*<br> **Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.**<br>

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A

---

| | |
|:---|:---|
| **PART I.** | **REGISTRANT INFORMATION.** |

---

Scorpius Holdings, Inc.

Full Name of Registrant

Former Name if Applicable

1305 E. Houston Street, Building 2

Address of Principal Executive Office (Street and Number)

San Antonio, TX 78205

City, State and Zip Code

---

| | |
|:---|:---|
| **PART II.** | **RULES 12B-25 (b) AND (c)** |

---

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

 ☐ (a) The reasons described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense; (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. 

---

| | |
|:---|:---|
| **PART III.** | **NARRATIVE** |

---

The Company is unable to file its Quarterly Report on Form 10-Q for its quarter ended September 30, 2025. The compilation, dissemination and review of the financial information required to be presented in the Form 10-Q has imposed time constraints on the Company's management that have rendered timely filing of the Form 10-Q impractical without undue hardship and expense to the Company. Furthermore, the registrant does not expect to be able to file the Form 10-Q within the extension period provided by Rule 12b-25.

---

| | |
|:---|:---|
| **PART IV.** | **OTHER INFORMATION** |

---

(1) Name and telephone number of person to contact in regard to this notification:

William Ostrander (919) 240-7133

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the Company was required to file such report(s) been filed? If the answer is no, identify report(s).

☐ Yes ☒ No

Form 10-Qs for the periods ended March 31, 2025 and June 30, 2025.

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings to be included in the subject report or portion thereof?

⌧ Yes ◻ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

The Company expects revenue for the three and nine months ended September 30, 2025 to be lower than the revenue for the three and nine months ended September 30, 2024 and net loss for the three and nine months ended September 30, 2025 to be higher than the net loss for the three and nine months ended September 30, 2024. The amounts are not yet determinable.

Scorpius Holdings, Inc. has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | SCORPIUS HOLDINGS, INC. | SCORPIUS HOLDINGS, INC. |
| Dated: November 18, 2025 | By: | /s/ William Ostrander |
|  |  | William Ostrander |
|  |  | Chief Financial Officer |

---